Our top pick for
Inari Medical, Inc is a medical devices business based in the US. Inari Medical shares (NARI) are listed on the NASDAQ and all prices are listed in US Dollars. Inari Medical employs 199 staff and has a trailing 12-month revenue of around USD$110.9 million.
|Latest market close||USD$71.2|
|52-week range||USD$39.55 - USD$84.91|
|50-day moving average||USD$69.7692|
|200-day moving average||USD$62.3306|
|Wall St. target price||USD$85.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.1242|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-13)||-3.23%|
|1 month (2020-10-22)||10.42%|
|3 months (2020-08-21)||1.01%|
|6 months (2020-05-22)||67.49%|
|1 year (2019-11-20)||N/A|
|2 years (2018-11-20)||N/A|
|3 years (2017-11-20)||N/A|
|5 years (2015-11-20)||N/A|
Valuing Inari Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inari Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Inari Medical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3458x. In other words, Inari Medical shares trade at around 3458x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Inari Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$15 million.
The EBITDA is a measure of a Inari Medical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$110.9 million|
|Operating margin TTM||12.45%|
|Gross profit TTM||USD$45.3 million|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$3.3 billion|
TTM: trailing 12 months
There are currently 1.3 million Inari Medical shares held short by investors – that's known as Inari Medical's "short interest". This figure is 26.1% up from 1.0 million last month.
There are a few different ways that this level of interest in shorting Inari Medical shares can be evaluated.
Inari Medical's "short interest ratio" (SIR) is the quantity of Inari Medical shares currently shorted divided by the average quantity of Inari Medical shares traded daily (recently around 261645.04132231). Inari Medical's SIR currently stands at 4.84. In other words for every 100,000 Inari Medical shares traded daily on the market, roughly 4840 shares are currently held short.
However Inari Medical's short interest can also be evaluated against the total number of Inari Medical shares, or, against the total number of tradable Inari Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inari Medical's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Inari Medical shares in existence, roughly 30 shares are currently held short) or 0.0712% of the tradable shares (for every 100,000 tradable Inari Medical shares, roughly 71 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inari Medical.
Find out more about how you can short Inari Medical stock.
We're not expecting Inari Medical to pay a dividend over the next 12 months.
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.